Last reviewed · How we verify

FUZEON [enfuvirtide] — Competitive Intelligence Brief

FUZEON [enfuvirtide] (FUZEON [enfuvirtide]) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV fusion inhibitor. Area: Infectious Disease / Virology.

marketed HIV fusion inhibitor gp41 (HIV envelope glycoprotein) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

FUZEON [enfuvirtide] (FUZEON [enfuvirtide]) — Hoffmann-La Roche. Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FUZEON [enfuvirtide] TARGET FUZEON [enfuvirtide] Hoffmann-La Roche marketed HIV fusion inhibitor gp41 (HIV envelope glycoprotein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV fusion inhibitor class)

  1. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FUZEON [enfuvirtide] — Competitive Intelligence Brief. https://druglandscape.com/ci/fuzeon-enfuvirtide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: